



## ASX ANNOUNCEMENT

### Substantial shareholder disclosure

For Immediate Release:

May 30, 2017

**Sydney, Australia** – Simavita Limited (“**Simavita**” or the “**Company**”) (ASX: SVA) refers to the announcement released on May 29, 2017 for the issue of 21,202,734 CHESS Depositary Interests (**CDIs**).

Further to the recent Rights Issue, there has been a change of more than 1% in the holdings of Daniel Hegglin and his associates (Hegglin) (6.69% reduced to 5.42%).

For further information, please check our website ([www.simavita.com](http://www.simavita.com)) or contact:

Ms Peta Jurd

Chief Commercial Officer

E: [pjurd@simavita.com](mailto:pjurd@simavita.com)

T: +61 421 466 653

W: Investor Centre: [Click here](#)

#### About Simavita

Simavita (ASX: SVA) develops and markets advanced systems associated with smart, wearable and disposable sensors for the health care industry. Our first products focus on major unmet needs for the assessment and management of incontinence. The annual global economic burden is billions of dollars for incontinence diapers alone and is increasing rapidly.

Simavita operates in Australia, Europe and North America where there is a significant and growing demand for products that deliver real clinical and cost benefits to the health care industry.

With the support of our shareholders, customers and employees, Simavita is absolutely committed to the business at hand; creating a commercially successful and growing corporation. [www.simavita.com](http://www.simavita.com)